Integrating Effective Therapeutic Strategies and Patient Management Tactics into Personalized Treatment Plans within COPD

Expert faculty will analyze data from the American Academy of Allergy, Asthma and Immunology 2015 Annual Meeting and present it in a matter that will aid physicians in clinical decision-making and enhancing patient care. New treatment options for special populations of asthma patients, including aspirin-exacerbated asthmatics will be explored. The mechanism of action of biologic therapies, diagnostic techniques, and deep phenotyping will be discussed in order to create a more patient-centered and precision medicine approach to asthma management. This CME program will provide practitioners with the most up-to-date information regarding patient management care in asthma.

TARGET AUDIENCE 

This activity is intended for allergists/immunologists, pulmonologists, primary care physicians, and other healthcare clinicians responsible for the care of patients with asthma.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be able to:

  1. Review the pathophysiology of asthma and symptoms associated with disease progression.
  2. Examine the mechanism of action of targeted biologic therapies, and analyze their role in asthma treatment, including within special patient populations.
  3. Integrate patient communication and education strategies into personalized treatment plans in order to optimize outcomes in asthma management.

Faculty

Reynold A. Panettieri, Jr, M.D.
Robert L. Mayock and David A. Cooper Professor of Medicine
Director, Airways Biology Initiative
Adjunct Professor, Wistar Institute
Deputy Director, Center of Excellence in Environmental Toxicology
Perlman School of Medicine
University of Pennsylvania
Pulmonary, Allergy, & Critical Care Division
Philadelphia, Pennsylvania

Andrew G. Weinstein, M.D.
Associate Clinical Professor Pediatrics
Jefferson Medical College
Philadelphia, Pennsylvania

 

Sidney Braman, MD
Professor Medicine
Director, Pulmonary Disease Management
Division of Pulmonary, Critical Care, & Sleep Medicine
Ichan School of Medicine at Mount Sinai
New York, New York

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty                                  

Relationship Identified With:

Reynold A. Panettieri, Jr, MD

Consultant/Advisor: AstraZeneca; Johnson & Johnson Services, Inc.

Grant/Research Support: Gilead Sciences, Inc.; Johnson & Johnson Services, Inc. ; Merck & Company, Inc.; F. Hoffmann-La Roche Ltd; Sanofi-aventis US LLC.

Andrew G. Weinstein, MD

Consultant/Advisor: Asthma and Allergy Foundation of America.

Grant/Research Support: Keystone First; Merck & Company, Inc.; National Institutes of Health.

Sidney Braman, MD

Consultant/Advisor: Boehringer Ingelheim GmbH; GlaxoSmithKline plc;  Genentech, Inc.; Meda Pharmaceuticals Inc; Teva Pharmaceutical Industries Ltd.

Planners, Managers, Reviewers: Sandy Breslow; Brynne Hunter; Jacquelyn Valerio; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Bernard Abrams, MD  hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months. 

Financial Support

This activity has been supported by an independent educational grant from Genentech, Inc.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.



Course Open Date: May 15, 2015 | Course Expiration Date: May 14, 2016

Accreditation Statement 

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The Elsevier Office of Continuing Medical Education designates this activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME and Genentech, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Course opens: 
05/15/2015
Course expires: 
05/14/2018
Rating: 
0

Available Credit

Accreditation Period

Course opens: 
05/15/2015
Course expires: 
05/14/2018
Please login or register to take this course.